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Peripheral nerve myelin facilitates rapid impulse conduction and normal motor and sensory functions. Many aspects of myelin biogen-
esis, glia–axonal interactions, and nerve homeostasis are poorly understood at themolecular level. We therefore hypothesized that only
a fractionof all relevantmyelinproteinshasbeen identified so far. Combining gel-basedandgel-freeproteomic approaches,we identified
545 proteins in purifiedmouse sciatic nervemyelin, including 36 previously knownmyelin constituents. Bymass spectrometric quanti-
fication, the predominant P0, periaxin, and myelin basic protein constitute 21, 16, and 8% of the total myelin protein, respectively,
suggesting that their relative abundance was previously misestimated due to technical limitations regarding protein separation and
visualization. Focusing on tetraspan-transmembrane proteins, we validated novel myelin constituents using immuno-based methods.
Bioinformatic comparison with mRNA-abundance profiles allowed the categorization in functional groups coregulated during myelin
biogenesis and maturation. By differential myelin proteome analysis, we found that the abundance of septin 9, the protein affected in
hereditary neuralgic amyotrophy, is strongly increased in a novel mousemodel of demyelinating neuropathy caused by the loss of prion
protein. Finally, the systematic comparison of our compendium with the positions of human disease loci allowed us to identify several
candidate genes for hereditary demyelinatingneuropathies. These results illustrate how the integrationof unbiasedproteome, transcrip-
tome, and genome data can contribute to a molecular dissection of the biogenesis, cell biology, metabolism, and pathology of myelin.
Introduction
Normal sensation and motor capabilities require fast nerve im-
pulse transmission. In vertebrates, this is achieved by the en-
sheathment of axons with myelin that restricts action potentials
to the nodes of Ranvier (Salzer et al., 2008). In the peripheral
nervous system (PNS), myelin is comprised of multiple com-
pacted layers of the molecularly specialized plasma membrane
extended from Schwann cells. Adaxonal and abaxonal myelin are
connected by cytoplasmic incisures that contain cytoskeleton,
vesicles, and outposts of endoplasmic reticulum and Golgi appa-
ratus (Perkins et al., 2008), which likely are relevant for myelin
maintenance and turnover. So far, only 45 distinct proteins
have been associated with PNS myelin, suggesting that knowl-
edge of the proteins required for normal myelin biogenesis, me-
tabolism, and interactions with axons has likely remained
incomplete. Moreover, the causative genes of several demyelinating
neuropathies remain unknown (Reilly and Shy, 2009).
The variety of PNSmyelin proteins has been considered low as
gel-electrophoretic separation followed by Fast Green or Coo-
massie staining yielded only three predominant bands which, in
the order of increasing mobility, were designated P0, P1, and P2
(Greenfield et al., 1973; Whitaker, 1981). Their relative abun-
dance was estimated to be 45–70%, 2–26%, and 1–15% of the
total myelin protein, respectively. P0 [myelin protein zero
(MPZ)], an immunoglobulin-like cell-adhesion molecule (Ig-
CAM), mediates adhesion of the extracellular myelin membrane
surfaces (D’Urso et al., 1990; Filbin et al., 1990; Giese et al., 1992),
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while P1 [now termed myelin basic protein, (MBP)] mediates
intracellular adhesion (for review, see Boggs, 2006). P2 (also
termed PMP2 or fatty acid-binding protein-8) is a lipid-
associated protein of unknown function (Trapp et al., 1984;
Chmurzyn´ska, 2006).
It became evident that PNS myelin contains more proteins
than assumed upon the immunoblot-based demonstration that a
known CNS myelin component, the Ig-CAM myelin-associated
glycoprotein (MAG), is also present in PNS myelin (Figlewicz et
al., 1981). Later, additional myelin proteins were identified by
using myelin-directed antibodies or amino acid sequence infor-
mation gained from purified myelin, such as the tetraspan pe-
ripheralmyelin protein of 22 kDa (PMP22) (Welcher et al., 1992)
and the scaffolding protein periaxin (PRX) (Gillespie et al., 1994).
More recently, the analysis of sciatic nerve mRNA abundance
profiles during myelin biogenesis or experimental hypomyelina-
tion (Verheijen et al., 2003; Buchstaller et al., 2004; D’Antonio et
al., 2006; Ryu et al., 2008) increased the number of myelin pro-
teins to40.
Considering the complexity of the CNS myelin proteome
(Ishii et al., 2009; Jahn et al., 2009), we hypothesized that many
more PNS myelin proteins await discovery. By subjecting puri-
fiedmyelin to various separation techniques andmass spectrom-
etry (MS), we identified 36 established myelin constituents and
500 proteins not previously associated with PNS myelin, and
readjusted their relative abundance. Integrating our compendium
with other systematic approaches and focusing on tetraspan-
transmembrane proteins, we illustrate how this resource can be ex-
ploited to gain comprehensive knowledge on groups of myelin
proteins defined by structural similarity, functional relationship, or
coregulated expression. This first PNS myelin proteome analysis
thusprovides aversatile framework for systematic analysesofmyelin
andmyelin-related diseases.
Materials andMethods
Animals.Male wild-type mice (C57BL/6N) at the age of postnatal day
28 (P28) were used, unless indicated otherwise. All experiments were
in compliance with the animal policies of the Max-Planck-Institute of
Experimental Medicine, approved by the German federal state of
Niedersachsen.
Myelin purification. A light-weight membrane fraction enriched for
myelin was purified from mouse sciatic nerves homogenized in 0.27 M
sucrose according to Larocca and Norton (2007). The protein concen-
tration was determined using the 2-D Quant kit according to the
manufacturer (GE Healthcare). Where indicated, purified myelin was
subjected to further high-salt and high-pHwashing/centrifugation cycles
as described previously (Werner et al., 2007) to enrich transmembrane
proteins before proteome analysis.
Gel electrophoresis and identification of gel-separated proteins. 2D-
isoelectric focusing (IEF)/SDS-PAGE was performed as described previ-
ously (Werner et al., 2007) with the difference that myelin was
delipidated and precipitated bymethanol/chloroform treatment (Wessel
and Flu¨gge, 1984) before IEF. The pellet was resuspended in lysis buffer
(20mMTris/HCl pH9.0, 7 M urea, 2 M thiourea, 2%ASB-14), centrifuged
(2 min, 16,000  g), and the protein concentration of the supernatant
was determined using the 2-D Quant kit (GE Healthcare). A volume
corresponding to 250 g of myelin was diluted 1:1 with 2 IEF sample
buffer (7 M urea, 2 M thiourea, 2% ASB-14, 1% ampholytes, 0.6% DTT)
and incubated for 30 min at room temperature. Finally, the sample was
filled up with rehydration buffer (7 M urea, 2 M thiourea, 2% ASB-14,
0.5% ampholytes, 0.3% DTT) to a volume of 350 l, centrifuged (2 min
16,000  g), and the supernatant subjected to IEF in immobilized pH
gradient (18 cm Immobiline nonlinear, pH 3–11, GE Healthcare) for
45 kVh. After completion of IEF, the proteins were reduced with DTT
and alkylated with iodoacetamide as described previously (Werner et al.,
2007). Second dimension SDS-PAGE was performed on 20  20 cm
gradient gels (8–16% acrylamide). Proteins were visualized by colloidal
Coomassie staining with Coomassie Brilliant Blue G-250 according to
Neuhoff et al. (1988). Approximately 500 gel plugs from each of two
independent gels were manually excised and subjected to an automated
platform for the identification of gel-separated proteins (Jahn et al.,
2006), as recently applied in large-scale proteome studies (Reumann et al.,
2007; Werner et al., 2007). An Ultraflex matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometer (Bruker Dal-
tonics) was used to acquire both peptide mass fingerprint (PMF) and
fragment ion spectra, resulting in confident protein identifications based on
peptidemass and sequence information.Database searches in theSwiss-Prot
primary sequencedatabase restricted toMusmusculuswereperformedusing
theMascot Software 2.2 (Matrix Science). Carboxamidomethylation of Cys
was specified as fixed and oxidation of Met as variable modification. One
missed trypsin cleavagewas allowed.Mass toleranceswere set to100ppmfor
PMF searches and to 100 ppm (precursor ions) and 0.7 Da (fragment ions)
forMS/MSionsearches.Theminimal requirement foracceptingaproteinas
identified was at least one peptide sequence match above identity threshold
in coincidence with at least 20% sequence coverage in the PMF.
One-dimensional (1D) SDS-PAGE was performed on precast NuPAGE
Bis-Tris 4–12% gradient gels using 2-(N-morpholino)ethanesulfonic acid
(MES) or 3-(N-morpholino)propanesulfonic acid (MOPS) buffer systems
according to the manufacturer (Invitrogen). Proteins were visualized by
Coomassie staining (see above) or silver staining according to Blum et al.
(1987). For systematic protein identification, 25g of untreatedmyelin was
separated and a total of four lanes from independent gels were sliced into 24
uniform pieces. 2D-16-benzyldimethyl-n-hexadecylammonium chloride
(16-BAC)/SDS-PAGEwasperformedasdescribedpreviously (Werner et al.,
2007). Briefly, 300–400 g of purified myelin was subjected to washing/
centrifugation cycles (see above), the final pelletwas resuspended in 16-BAC
sample buffer, andproteinswere separatedon7.5%acrylamide 16-BACgels
(20 20 cm) as described previously (Hartinger et al., 1996; Werner et al.,
2007).Two-dimensionalSDS-PAGEwasperformedon2020cmgradient
gels (8–16% acrylamide). Proteins were visualized by colloidal Coomassie
staining (see above), and approximately 100 gel plugs each from two inde-
pendent gels were excised. To account for the lower resolution of 1D-SDS-
PAGE and 2D-16-BAC/SDS-PAGE (resulting in more complex peptide
mixtures after in-gel digestion), these gel systems were interfaced to protein
identificationbynano-flowHPLC-MS/MS.Bands from1D-SDS-PAGEgels
or plugs from 2D-16-BAC/SDS-PAGE gels were subjected to tryptic in-gel
digestion, and the released peptides were extracted in two consecutive steps
with 0.5% trifluoroacetic acid (TFA)/10% acetonitrile and 0.5% TFA/50%
acetonitrile, respectively. Pooled extracts were dried, redissolved in 0.1%
TFA,andsubjected toreversedphase separationonanUltimatenano-HPLC
system (Dionex) as described previously (Galli et al., 2009). Peptides were
desalted andpreconcentrated on a 2 cm 75mcolumn (packed in-house
withReprosil-PurC18-AQmaterial of 5mparticle and100Åpore size;Dr.
Maisch)with 0.1%TFAat a flow rate of 8l/min. Separationon15 cm 75
m columns (packed in-house with the same material as above) was per-
formed at 40°C with a flow rate of 250 nl/min. Peptides were directly eluted
into an ESI ion trap LCQDeca XP Plus mass spectrometer (Thermo Fisher
Scientific) with the acquisition duty cycle set to a full-scan mass spectrum
(mass-to-charge ratio 400–1500) followedby three data-dependentMS/MS
scans. Mascot database searches were performed as for the MALDI-TOF-
MS/MS data with the difference that the mass tolerance was 1.5 Da for the
precursor ions and 1.0 Da for the fragment ions. The minimal requirement
for accepting a protein as identified was at least two peptide sequence
matches above identity threshold. Protein identifications on the basis of a
single peptide were considered when the score was at least two times higher
than the identity threshold and were accepted only after manual inspection
of the mass spectrum.
2D-differential fluorescence-intensity gel electrophoresis (2D-DIGE)
was used for differential proteome analysis of sciatic nerve myelin puri-
fied from 4-week-old mice with a deletion of the prion protein gene
(Prnp0/0) backcrossed to the BALB/c background (Bremer et al., 2010)
and wild-type BALB/c controls. 2D-DIGE was essentially performed as
described for CNS myelin (Werner et al., 2007). Briefly, wild-type and
Prnp0/0 myelin proteins from two independent preparations each were
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labeled twice, thereby swapping the dyes, resulting in four samples that
were subjected to 2D-IEF/SDS-PAGE in parallel. Per channel, 80 g of
protein was labeledwith 400 pmol of the respective Cy-dye. Fluorescence
images were processed with the Proteomweaver software (version 4.0,
Bio-Rad), and spots were accepted as significantly different for p 0.05
(Student’s t test).
Gel-free proteome analysis and GeLC-MSE. For gel-free analysis, 25 g
of total myelin protein was precipitated using the ProteoExtract Protein
Precipitation Kit (Calbiochem), solubilized in 50 mM NH4HCO3 with
0.1% Rapigest (Waters) (10 min, 85°C), reduced with 5 mM DTT (45
min, 56°C), and alkylated with 15 mM iodoacetamide (45 min, room
temperature) in the dark. Solubilized proteins were digested with 0.5 g
of sequencing grade trypsin (Promega) for 16 h (37°C). After digestion,
Rapigest was hydrolyzed by adding 10 mM HCl, the resulting precipitate
was removed by centrifugation (13,000 g, 15min, 4°C), and the super-
natant was transferred into an autosampler vial for ultraperformance
liquid chromatography (UPLC) coupled to MS with an alternating low
and elevated (E) energy mode of acquisition-(MSE). Alternatively, for
gel-enhanced liquid chromatography (GeLC)-MSE analysis, 25 g of
total myelin protein were separated by 8–16% SDS-PAGE, the resulting
gel lanes were cut into 11 equally sized pieces, and in-gel digestion was
performed as described above. For UPLC-MSE-analysis, UPLC separa-
tion of tryptic peptides and on-line analysis by quadrupole-TOF (QTOF)
mass spectrometry were performed as described previously (Kra¨mer-
Albers et al., 2007).
The continuum LC-MSE data were processed and searched using the
IDENTITYE-algorithmof ProteinLynxGlobal Server (PLGS) version 2.3
(Waters). Protein identifications were assigned by searching the Uni-
ProtKB/Swiss-Prot Protein Knowledgebase Release 52.3 for mouse pro-
teins (12,920 entries) supplemented with known possible contaminants
(porcine trypsin, human keratins) using the precursor and fragmenta-
tion data afforded by LC-MS acquisition as described previously
(Kra¨mer-Albers et al., 2007). Mass tolerances for peptide and fragment
ions were set at 15 and 30 ppm, respectively. Peptide identifications were
restricted to tryptic peptides with no more than one missed cleavage.
Carboxamidomethylation of Cys was set as fixed modification, and oxi-
dation of Met, acetylation of protein N termini, and deamidation of Asn
and Gln were searched as variable modifications. For a valid protein
identification, the following criteria had to be met: at least two peptides
detected together with at least seven fragments. The false-positive rate for
protein identification was set to 1% based on search of a 5 randomized
database, whichwas generated automatically using PLGS 2.3 by reversing
the sequence of each entry. By using replication rate as a filter, the false-
positive rate was further minimized, as false-positive identifications do
not tend to replicate across injections due to their random nature. By
requiring a protein identification to be made in at least three technical
replicates, the effective false-positive rate was lowered to0.2%.
In situ hybridization.Probeswere generated byPCRamplification of total
brain cDNA using primers specific for Cd151 (forward 5-TACCTGCTCT
TTACCTACAACTGCT, reverse 5-GAAGGTCTCCAGCTTAGTGATA-
CAG); Cmtm5 (forward 5-CTGTCTGCTT CTCTAACCAG ATTTCT,
reverse 5-GTGGAATATA GATGGTGGGT ACTTG); or Sept9 (forward
5-CTGGAGGAGAGGGTCTACTTCAAAC, reverse5-ACACATAGCTC
TTCTAACCCCT CAG); and subsequent cloning into pGemT (Promega).
The probeswere sequence validated.One-month-oldNMRIwild-typemice
were retrocardially perfused with alkaline phosphate buffer (aPB; 0.1 M
Na2HPO4, pH 9) containing 10% sucrose, followed by 6% formalin in aPB
containing 20%sucrose. Sciatic nerveswere isolated, fixed (1h, 6% formalin
in aPB containing 20% sucrose), rinsed (H2O), dehydrated (ascending alco-
hol row, 5min/50% ethanol, 10min/70% ethanol, 20min/90% ethanol, 30
min/100%ethanol, 45min isopropanol, 2 60min xylene), and embedded
in paraffin wax (2 90min, 60°C). Cross sections (10m)were cut using a
sliding microtome and collected on adhesive glass slides (SuperFrost/Plus).
Sectionsweremanuallydriedusing tissuepaper, incubated (37°C for 2hand
60°C for1h),deparaffinized, andrehydrated (descendingalcohol row220
min xylene, 10min isopropanol, 10min 100% ethanol, 5min 90% ethanol,
5 min 70% ethanol, and 2 min 50% ethanol); fixed [15 min in 4% parafor-
maldehyde (PFA) in PBS, pH 7.4], washed (in PBS), and incubated with 20
g/ml Proteinase K (in 20 mM Tris, pH 7.5/1 mM EDTA, pH 8, 2.5 min).
ProteinaseKwas inactivated (0.2%glycine inPBS); sectionswerewashed (in
PBS), fixed (4% PFA and 0.2% glutaraldehyde in PBS, 20 min), washed (in
PBS), prehybridized [hybridization buffer: 50% formamide, 5 SSC, 1%
blocking reagent (Roche), 5 mM EDTA, 0.1% Tween, 0.1% CHAPS, 0.1
mg/ml heparin, and 100g/ml yeast RNA] at 48°C for 2 h, hybridized over-
night at 48°C in hybridization buffer containing digoxigenin-labeled (DIG-
RNALabeling-Mix,Roche), anddenatured (95°C, 5min)with cRNAprobe;
washed (SSC, pH 4.5); treated with 20 g/ml RNase in 0.5 M NaCl/10 mM
Tris (30 min, 37°C); washed (2 SSC, pH 4.5); washed 3 in 50% forma-
mide in2SSC,pH4.5 (3min,37°C);washed(inKTBT:50mMTrispH7.5,
150mMNaCl, 10mMKCl, 1%Triton-X); blocked (2 h) in 20% sheep serum
in KTBT (Ab-block); incubated with anti-DIG alkaline phosphatase anti-
body(Roche)1:1000 inAb-block(overnight, 4°C);washed inKTBT;washed
4 in KTBT for 30 min, washed in 100 mM Tris, pH 9.5, 100 mMNaCl, 50
mM MgCl2, and 0.05% Tween20 (NTMT); developed in NBT/BCIP in
NTMT for 4–18 h at 37°C; washed 2 for 6 h in KTBT; counterstained (1
g/ml DAPI in PBS); dehydrated using a quick ascending alcohol row;
cleared in benzyl alcohol/benzyl benzoate 1:2; andmounted using Eukitt. If
not noted otherwise, incubations were at room temperature and washing
was 25min in a slowly (0.25Hz) shaking cuvette.All solutionsusedbefore
antibody incubation were prepared using RNase free (DEPC treated) H2O.
The sense probes and a probe for an unrelated, exclusively neuronalmRNA
(Neurod6) were processed in parallel as controls and gave no signal.
mRNA abundance profiles. Male wild-type mice (C57BL/6N) at the
ages of 1, 5, 15, or 65 d were subjected to cervical dislocation. The sciatic
nerves were isolated and homogenized, and total RNAwas extractedwith
Trizol reagent. RNA integrity and concentration were determined using
an Agilent 2100 Bioanalyzer. Biotinylated cRNAs for hybridization to
Affymetrix 3-arrays were prepared from 1 g of total RNA using Ge-
neChip One-Cycle Target Labeling and Control Reagents (catalog
#900493, Affymetrix). Labeled cRNA was fragmented and hybridized to
Mouse Genome 430 2.0 Arrays (3-arrays, catalog #900496, Affymetrix)
according to the manufacturer’s instructions. Raw image files were pro-
cessed using Affymetrix GCOS 1.3 software to calculate individual probe
cell intensity data and generate CEL Data Files. Statistical analyses have
been performed with R using packages Biobase, limma,marray, affy, and
masigpro. Data were filtered by reading out expression values for those
528 of 545 proteins that were identified inmyelin byMS and represented
on themRNA arrays. Sept9was also included, though SEPT9 protein was
detected byMS only in Prnp0/0myelin while it was below the significance
threshold in wild-type myelin. For comparison, eight known myelin
genes were included of which the corresponding proteins were not iden-
tified by MS (Pmp22, Mal, Cdh1, Ctnnb1, Mtmr2, Mp11/A330049/
M08Rik, Jam4/Igsf5, and Cx32/Gjb1). Data were normalized using the
robust multiarray average method. To facilitate clustering, we trans-
formed the data and set the mean value to zero and the SD to 1/1.
Transformed data were then subjected to K-means clustering. The
mRNA abundance dataset is available from the authors upon request.
QuantitativeRT-PCR.Sciaticnervesof5-week-oldPrnpO/Omice (Bremer
et al., 2010) backcrossed to the c57Bl/6 background, and age-matched
C57BL/6wild-typemicewere homogenized inTRIzol (Invitrogen) by using
PolytronPT3100 (Kinematica). RNAwas extracted andpurified onRNeasy
columns (Qiagen). cDNA was synthesized with QuantiTect Reverse Tran-
scription kit (Qiagen), and analyzed by real-time PCR using QuantiFast
SYBR Green PCR kit (Qiagen) and 7900HT (Fast Real-Time PCR systems,
AppliedBiosystems). Primerswere specific for Sept9 (forward5-ACTGCT-
GCCT CTACTTCAT, reverse 5-TCTGCGTCCT CATCAAACTC) or
GAPDH (forward 5-CCACCCCAGCAAGGAGACT, reverse 5-GAAAT-
TGTGAGGGAGATGCT).
Immunoblotting. Immunoblotting was performed as described previ-
ously (Werner et al., 2007). Antibodies were specific for PLP/DM20
(Jung et al., 1996), plasmolipin (Bosse et al., 2003), myelin and lympho-
cyte protein (MAL) (Schaeren-Wiemers et al., 2004), PMP22 (ab15506,
Abcam), CD9 (PharMingen), CD81 (PharMingen), CMTM5 (CKLF-
like MARVEL-transmembrane domain-containing protein 5, also
termed PETA-3; ab88964, Abcam; or M-13, Santa Cruz Biotechnology,
yielding similar results), CD151 [455807, R&D Systems (Cowin et al.,
2006)], septin 9 (SEPT9) [10769, Protein Tech Group and Nagata et al.,
(2004) (yielding similar results)], MAG (clone 513, Millipore Bioscience
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Research Reagents), 2,3-cyclic nucleotide phosphodiesterase (CNP;
11–5B, Sigma), COX4 (MS404,MitoSciences), and actin (Mab1501,Mil-
lipore Bioscience Research Reagents).
Immunoelectron microscopy. Immunolabeling of sciatic nerve cryosec-
tions and electron microscopy were as described previously (Werner et
al., 2007). Primary antibodies were specific for CMTM5 (ab88964, Ab-
cam; or M-13, Santa Cruz Biotechnology; yielding similar results),
CD151 [455807, R&D Systems (Cowin et al., 2006)], or septin 9 (10769,
Protein Tech Group).
Results
Purification of PNS myelin
For the purification of myelin, we have subjected sciatic nerve
homogenates of adult (P28) wild-type mice (C57BL6) to discon-
tinuous sucrose-gradient centrifugation, obtaining the myelin-
enriched fraction at the interface between 0.27 and 0.83M sucrose
(Larocca and Norton, 2007). When the myelin-enriched fraction
was compared with nerve homogenate by 1D-SDS-PAGE and
colloidal Coomassie stain, the number of bands was considerably
reduced and the intensity of bands constituted bymyelin proteins
such as P0 was enhanced (data not shown), in accordance with
numerous previous publications by several laboratories. As a pi-
lot approach to systematically identify the proteins contained in
the myelin-enriched fraction, 5 g of myelin was separated by
1D-SDS-PAGE using two different buffer systems (MES and
MOPS) for enhanced separation in the low- or high-molecular-
weight range, respectively (Fig. 1). Bands visualized by Coomas-
sie staining were excised and subjected to tryptic in-gel digestion,
and proteins were identified based on peptidemass and sequence
information obtained by MALDI-TOF-MS. While the coverage
of knownmyelin proteins was high, it became apparent that sev-
eral bands contained more than one protein. For example, P2
(calculated molecular mass 14.9 kDa) was not separated from
hemoglobin A (HBA; 15.1 kDa), a common contamination from
red blood cells. This suggests that insufficient protein separation
has impaired previous 1D-gel-based estimations of the abun-
dance of P2, and likely that of othermyelin proteins. Importantly,
themajority of bands were constituted by proteins not previously
associated with PNS myelin (Fig. 1, arrows). Together, this pilot
experiment supported our hypothesis that numerous myelin
constituents remain to be identified. As an attempt to fill this gap,
we have performed a systematic proteome analysis. For simplic-
ity, we will use the term “myelin” for the myelin-enriched frac-
tion isolated from sciatic nerves, and “myelin-associated” for all
proteins identified inmyelin, regardless of whether such localiza-
tion has been validated with independent methods.
Proteome analysis of PNS myelin
With the goal to establish a comprehensive compendium of PNS
myelin proteins, we have used a combination of various gel-based
and gel-free methods. Similar to the procedure described above,
25 g of myelin was prefractionated by 1D-SDS-PAGE (MES
buffer system, data not shown). The complete lanes were sliced
into 24 uniform pieces, and their analysis by HPLC coupled to
MS (GeLC) led to the identification of 144 proteins (marked “S”
in this article). The same technique was additionally applied to
myelin that underwent several wash cycles for the enrichment of
membrane proteins (wash-GeLC, 83 proteins, marked “wS”).
When prefractionation of washed myelin by 1D-SDS-PAGE
(25g of myelin, 11 gel slices) was combined with the LC-MSE
technology (see below), the number of identified proteins in-
creased by a factor of three (wash-GeLC-MSE 246 proteins,
marked “wSE”).
To improve separation and proteome coverage, and to pro-
vide reference maps, also two-dimensional protein separation
techniques were applied. First, 250 g of delipidated and precip-
itated myelin was separated using IEF with immobilized pH gra-
dients as the first dimension and SDS-PAGE as the second
dimension, and proteins visualized by colloidal Coomassie stain-
ing (Fig. 2A) were identified by an automated platform based on
MALDI-TOF-MS (2D-IEF/SDS-PAGE, 249 proteins, marked
“I”). Next, we subjected 400 g of myelin to the wash procedure
and separated the remaining proteins by 2D-16BAC/SDS-PAGE,
an alternative 2D gel system (Hartinger et al., 1996) suitable for
displaying myelin proteins (Werner et al., 2007). Proteins visual-
ized by colloidal Coomassie staining (Fig. 2B) were identified by
HPLC-MS/MS (2D-16BAC/SDS-PAGE, 53 proteins, marked
“B”). Collectively, gel-based techniques led to the identification
of 436 nonredundant proteins in purified sciatic nerve myelin
(Fig. 3A).
As gel-based methods may exhibit a bias toward certain pro-
tein classes and a limited dynamic range, we also applied gel-free
“shotgun” approaches to confirm and expand themyelin protein
compendium.We subjected 20 g of myelin to in-solution tryp-
tic digestion and analyzed the resulting complex peptide mixture
by UPLC coupled to a QTOF hybrid mass spectrometer. Data
were acquired in the conventional data-directed automatic anal-
ysis mode (LC-DDA; 169 proteins, marked “D”) and with an
alternating low/elevated collision energy acquisition mode (LC-
MSE; 296 proteins, marked “E”). The latter circumvents the typ-
ical undersampling of LC-DDA, thereby improving proteome
coverage (Fig. 3A) and allowing gel-free, label-free quantification
of the relative abundance of proteins (see below) (Silva et al.,
2005, 2006; Weinzierl et al., 2008). Finally, washed myelin was
also subjected to LC-MSE (wash-LC-MSE; 82 proteins, marked
“wE”). Together, gel-freemethods led to the identification of 330
nonredundant myelin-associated proteins (Fig. 3A).
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Figure 1. One-dimensional separation of PNSmyelin.Myelin purified fromwild-type sciatic
nerves was separated by SDS-PAGE in different buffer systems providing improved resolution
either in the low-molecular-weight (MES) or high-molecular-weight (MOPS) range. Proteins
were visualized by colloidal Coomassie staining (Coom.; 5g of protein load) or, for compari-
son, by silver staining (0.5 g of protein load). Coomassie-stained bands were subjected to
mass spectrometric protein identification. Bands constituted by known myelin proteins are
denoted. In bands marked with arrowheads, only proteins not previously associated with my-
elin were identified, indicating that the complexity of the PNS myelin proteome is higher than
previously assumed. Note that several bands containedmore than one protein (e.g., P2was not
separated from HBA), indicating that one-dimensional separation does not allow reliable esti-
mation of relative protein abundance. ANXA2, Annexin A2.
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When the results of the gel-based and
gel-free approaches were combined, a to-
tal of 545 nonredundant proteins were
identified with a high overlap of 221 pro-
teins (41%) detected by both methods
(Fig. 3A). The numbers of proteins iden-
tified by the various methods are com-
pared in Figure 3A. In particular, the
proteins of higher abundance have been
reproducibly identified with the major-
ity of techniques. The identification of
hundreds of proteins in PNS myelin
supports our hypothesis that the com-
plexity of its protein composition has
been underappreciated so far because
low-abundant components were over-
shadowed by dominant myelin compo-
nents due to technical limitations in protein
separation and staining.
Forty-four percent of the proteins iden-
tified in PNS myelin (this study) were also
identified in rodent CNSmyelin using sim-
ilar techniques (Taylor et al., 2004; Vanro-
baeys et al., 2005; Roth et al., 2006; Werner
et al., 2007; Baer et al., 2009; Jahn et al.,
2009) (Fig. 3B), which is surprisingly many
when considering that Schwann cells and
oligodendrocytes differ regarding their on-
togenic origin (neural crest and subven-
tricular zone, respectively), axonal segments
myelinatedper glial cell (1:1 andup to60:1),
and major myelin proteins (P0 and PLP)
(for review, seeMo¨bius et al., 2008).
Categorization of myelin proteins
We have categorized the proteins identi-
fied in sciatic nerve myelin as (1) mem-
brane spanning, (2) cytosolic, and (3)
extracellular myelin-associated proteins,
and likely contaminants from (4) mito-
chondria, (5) nuclei, (6) blood, and (7)
hair (Fig. 3A).
Thecategory“membrane spanning”was
based on calculations using TMHMM
(v2.0)(smart.embl-heidelberg.de),Phobius/
TMHMM (phobius.sbc.su.se), and Scampi
(scampi.cbr.su.se). Sixty-three membrane-
spanning proteinswere identified (Table 1),
including established myelin proteins such
as P0 (D’Urso et al., 1990; Filbin et al., 1990;
Giese et al., 1992); MAG (Figlewicz et al.,
1981); sarcoglycan- (Cai et al., 2007), nec-
tin-like protein-4 (NECL4) (Spiegel et al.,
2007); and the tetraspan-transmembrane
proteins proteolipid protein (PLP/DM20),
plasmolipin (PLLP), CD81, and CD9 (Gar-
bern et al., 1997; Bosse et al., 2003; Ishibashi
et al., 2004). Tetraspans have been impli-
cated in a variety of important myelin-
related cellular events such as glial cell
migration and growth regulation, organelle
trafficking, myelin biogenesis and ultra-
structure, and membrane adhesion (Bron-
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Figure 2. Two-dimensionalmyelin proteomemaps.A,B,Myelin purified fromwild-type sciatic nerveswas separated in different gel
systems, andproteins visualizedby colloidal Coomassie stainingwere subjected tomass spectrometric protein identification. Representa-
tivegels are shown. Theprotein identities of all individual spotswill behostedon theauthor’swebpage (seeNotes). Thismaterial hasnot
been peer reviewed.A, 2D-IEF/SDS-PAGEwith IEF in a nonlinear pH gradient (3–11) as the first and SDS-PAGE as the second dimension.
Proteinswere identifiedbyanautomatedplatformbasedonMALDI-TOF-MS(485unequivocal identifications from528pickedspots).B,2D-16-
BAC/SDS-PAGEwith separation in a 16-BAC gel as the first and SDS-PAGE as the second dimension. Proteinswere identified by HPLC-MS/MS to
addressthehighersamplecomplexityresultingfromthelimitedresolutionofthegel(74identificationsfrom94pickedspots).
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stein, 2000; Gould et al., 2005). Moreover, several myelin tetraspans
cause neuropathies when mutated. Therefore, we have chosen those
tetraspansthathavenotpreviouslybeenassociatedwithmyelin,CD151,
andCMTM5, for antibody-based validation thatmyelin proteins were
indeednewly identified in our compendium(see below).
The category “cytoplasmic” contained the vast majority of
identified proteins (Fig. 3A), includingmany knownmyelin pro-
teins as MBP, fatty acid synthase (FASN), carbonic anhydrase
(Cammer and Tansey, 1987), P2 (Trapp et al., 1984), CNP (Mat-
thieu et al., 1980), the NAD-dependent deacetylase Sirtuin-2
(SIRT2) (Werner et al., 2007), gelsolin (Gonc¸alves et al., 2010),
cdc42 (Benninger et al., 2007), crystallin-2 (D’Antonio et al.,
2006), band 4.1 G-protein (Ohno et al., 2006), dystrophin-
related protein-2 (DRP2) (Sherman et al., 2001), ERM proteins
(ezrin, radixin, moesin) (Scherer et al., 2001), and small
cytoskeleton-associated GTPases of the septin family (SEPT2,
SEPT7, SEPT11) (Buser et al., 2009). The high coverage of known
myelin proteins indicates that our proteomic approach is suitable
for systematic analysis.
Since PNSmyelin is tightly associated with the extracellular ma-
trix, it was also expected to identify various collagen types and basal
lamina proteins (Fig. 3A). Indeed, Laminin 1 (Chen and Strick-
land, 2003) and various proteoglycans (decorin, lamican,mimecan/
osteoglycin, perlecan) were identified that may modulate the
function of recognition molecules for axo-glial interactions
(Chernousov and Carey, 2000), such as integrin 6 (Nodari et al.,
2008) and1 (Feltri et al., 2002), whichwere also identified. Among
the identified extracellular proteins, CNTF has been previously
shown to be a Schwann cell-derived protein supporting axonal de-
velopment and regeneration (Sendtner et al., 1994). This suggests
that proteomic analysis of PNS myelin has the capacity to identify
signaling proteins relevant for Schwann cell development.
Although we expect that a very high proportion of proteins
identified for the first time in the myelin-enriched fraction are
indeed true myelin constituents, somemay only have copurified,
such as proteins associated with mitochondria, which have flota-
tion properties in sucrose gradients similar to myelin. Proteins
were categorized as being of mitochondrial origin according to
predictions using CELLO (cello.life.nctu.edu.tw), TARGETP
(cbs.dtu.dk/services/TargetP), WOLFPSORT (wolfpsort.org),
SUBLOC (bioinfo.tsinghua.edu.cn/SubLoc), and previous ap-
pearance in a mitochondrial proteome compendium (Mito-
Carta) (Pagliarini et al., 2008) (Fig. 3A). However, the fact that a
considerable number of proteins display a dual cytoplasmic and
mitochondrial localization (Pagliarini et al., 2008) prompted us
to not exclude any protein from the compendium because of
predicted subcellular localization. Only very few proteins were
recognized as likely contaminations from nuclei, blood, and hair.
CMTM5 and CD151 are novel myelin tetraspan proteins
The proven relevance of tetraspan-transmembrane proteins for
myelin (for review, see Bronstein, 2000) led us to select such
proteins fromour dataset for experimental validation that indeed
myelin proteins were newly identified. Immunoblotting revealed
that both CMTM5 and CD151 were abundant in the myelin-
enriched fraction (Fig. 4A). For comparison,markers of compact
myelin such as the tetraspans PMP22, PLP/DM20, and MAL
(Schaeren-Wiemers et al., 2004) were enriched in myelin relative
to lysates, markers of uncompact myelin (MAG, CNP) were de-
tected with approximately equal abundance in myelin and ly-
sates, while contaminating actin and the mitochondrial marker
COX4 were barely detectable in the myelin-enriched fraction. In
situ hybridization of sciatic nerves using cRNAprobes specific for
Cmtm5 and Cd151 led to signals consistent with strong expres-
sion in Schwann cells (Fig. 4B,C). To identify the exact localiza-
tion of CMTM5 and CD151, we have applied cryo-immuno
electron microscopy to cross-sectioned sciatic nerves. CMTM5
was prominently labeled in compact myelin (Fig. 4D) and at the
endoplasmic reticulumof Schwann cells (Fig. 4D), while CD151
was detected in compact myelin (Fig. 4E) and at the plasma
membrane of myelinating Schwann cells (Fig. 4E). Labeling was
virtually absent from other structures (for overviews, see Fig.
4D,4E). In particular, Schmidt–Lanterman incisures andmito-
chondria were not labeled. Together, we have validated the pres-
ence of two novel tetraspans with distinct distributions in normal
PNSmyelin. Togetherwith the finding that at least 36 proteins iden-
tified by MS in myelin are known myelin constituents, this raises
confidence that our compendium has strong predictive value
with respect to novel myelin constituents.
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Figure 3. Comparison of approaches to the PNSmyelin proteome, and comparisonwith the
CNSmyelin proteome.A, Proteins identified in purifiedwild-type PNSmyelin by eight different
technical approaches were categorized according to subcellular localization. Transmembrane
domains were predicted with TMHMM2, PredHel/Phobius, and Scampi. Classification as mito-
chondrial was based on predictions using CELLO, TARGETP, WOLFPSORT, SUBLOC, and compar-
ison with the brain mitochondrial proteome (MitoCarta). Extracellular proteins were classified
based on CELLO, TARGETP, WOLFPSORT, SUBLOC, Swiss-Prot, NCBI-Gene, and according to the
literature. Methods: S, GeLC; wS, wash-GelC; wSE, wash-GeLC-MS E; I, 2D-IEF/SDS-PAGE; B,
2D-16BAC/SDS-PAGE; D, LC-DDA; E, LC-MS E; wE, wash-LC-MS E (see text for details). B, Venn
diagram comparing the number of proteins identified by MS in PNS myelin (this study) with
those previously identified in rodent CNS myelin (Taylor et al., 2004; Vanrobaeys et al., 2005;
Roth et al., 2006;Werner et al., 2007; Baer et al., 2009; Jahn et al., 2009). Note the high overlap
of proteins identified in myelin from both sources.
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Table 1. Transmembrane proteins identified by MS in peripheral myelin
Protein name Gene MSmethod Phobius Scampi TMHMM
ADP/ATP translocase 1, Slc25a4 Slc25a4 wSE 2 0 3
ADP/ATP translocase 2, Slc25a5 Slc25a5 wSE 1 0 2
ADP/ATP translocase 4, Slc25a31 Slc25a31 wSE 2 0 2
ADP-ribosyltransferase 3 Art3 E 1 0 0
Amyloid-like protein 1 Aplp1 E 1 2 1
Basigin Bsg wSE 1 2 1
Ca 2 ATPase 1 Atp2a1 D, E, wSE 8 8 7
Ca 2 ATPase slow twitch 2 Atp2a2 wSE 9 9 8
Calnexin Canx S, D, wS, wSE 1 2 1
Caveolin 1 Cav1 S, E, wSE 1 2 1
CD151 Cd151 S, wS 4 4 4
CD81 Cd81 D, E, wE, wSE 4 4 4
CD9 Cd9 S, D, E, wS, wE, wSE 4 4 4
Cell adhesion molecule 3, NECL1 Cadm3 E, wSE 1 2 1
Cell adhesion molecule 4, NECL4 Cadm4 I, S, D, E, wS, wSE 1 2 1
Cell cycle exit and neuronal diff. Cend1 S, wSE 1 1 1
Choline transporter-like protein 1 Slc44a1 D, E 9 12 9
CKLF-like MARVEL TMD-containing 5 Cmtm5 wS, wSE 4 4 4
Claudin 19 Cldn19 wSE 5 4 4
Complement C3 C3 B, S, D, E, wSE 0 3 1
Cyclophilin B Ppib I, E 0 1 1
Cytochrome B5 Cyb5a wSE 1 1 1
Cytochrome c oxidase 2 Mtco2 wSE 2 2 2
Cytochrome c oxidase 4 isoform 1 Cox4i1 wS, wSE 1 1 1
Cytochrome c oxidase 6C Cox6c wSE 1 1 1
Cytoskeleton-associated protein 4 Ckap4 B, wSE 1 1 1
Dehydrocholesterol reductase Dhcr7 wSE 9 8 6
Dolichyl-oligosaccharide glycosyltransferase Ddost wSE 1 2 2
Ectonucleoside triphosphate diphosphatase 2 Entpd2 wSE 1 3 2
Endoplasmic reticulum protein ERp29 Erp29 I 0 1 1
Extended synaptotagmin-like 1 Fam62a wSE 1 5 1
Fucosyltransferase 8 Fut8 B 1 1 1
Hydroxysteroid (17-) dehydrogenase 12 Hsd17b12 wSE 1 1 1
Integrin6 Itga6 I, D, wSE 1 3 1
Integrin1 Itgb1 wSE 1 3 1
K ATPase1 Atp4a E 8 8 8
K ATPase2 Atp12a E 10 10 8
Malectin Mlec I 1 2 1
Myelin-associated glycoprotein Mag S, D, E, wS, wSE 1 2 1
Myelin protein zero, P0 Mpz I, B, S, D, E, wS, wE, wSE 1 2 2
Myelin proteolipid protein Plp1 B, S, D, E, wS, wE, wSE 4 4 4
Na/K ATPase1 Atp1a1 S, D, E, wS, wE, wSE 8 10 10
Na/K ATPase2 Atp1a2 S, E, wS, wSE 8 10 8
Na/K ATPase3 Atp1a3 S, D, E, wSE 8 10 8
Na/K ATPase4 Atp1a4 E, wSE 10 10 10
Na/K ATPase1 Atp1b1 D, E, wS, wE, wSE 1 1 1
Na/K ATPase3 Atp1b3 E 1 1 1
NAD(P) dependent steroid dehydrogenase-like Nsdhl wSE 1 1 1
NADH-ubiquinone dehydrogenase 1a4 Ndufa4 wSE 1 1 1
Plasmolipin Pllp S, E, wS, wSE 4 5 4
Progesterone receptor membrane component 1 Pgrmc1 wSE 1 1 1
Receptor accessory protein 5 Reep5 wSE 2 4 2
Reticulon 3 Rtn3 wSE 3 4 3
Reticulon-4, NoGo Rtn4 B, S 3 4 2
Ribophorin 1 Rpn1 wSE 1 2 1
Ribophorin 2 Rpn2 B 3 4 3
S100-A10 S100a10 I, S 1 0 1
Sarcoglycan  Sgcd wSE 1 1 1
Sideroflexin 3 Sfxn3 wSE 2 3 2
Solute carrier 25a3 Slc25a3 wS, wSE 2 3 2
Thy-1 membrane glycoprotein Thy1 wSE 1 1 0
Ubiquitin-specific peptidase 19 Usp19 wS 1 3 1
UDP galactosyltransferase 8 Ugt8 wSE 1 4 2
For all proteins identified by MS in myelin, transmembrane domains (TMDs) were predicted using three algorithms (Phobius, Scampi, TMHMM). In this table, all proteins with at least one TMDwere compiled, and tetraspan-TMD proteins
(bold) were selected for experimental validation of their presence in myelin. Identification methods are as follows: S, GeLC; wS, wash-GelC; wSE, wash-GeLC-MSE; I, 2D-IEF/SDS-PAGE; B, 2D-16BAC/SDS-PAGE; D, LC-DDA; E, LC-MSE; wE,
wash-LC-MSE. The complete compendium of MS-identified proteins, including nontransmembrane proteins, will be hosted on the author’s web page (see Notes).
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Relative abundance of myelin proteins
As a label-free MS-based quantification approach, LC-MSE can
provide information regarding the relative abundance of pep-
tides, and thereby the corresponding proteins, in a complex sam-
ple.We have calculated the relative abundanceofmyelinproteins as
identified by LC-MSE based on the average intensity of the three
most abundant unique peptides per protein. In the few cases for
which only two peptides were identified, their average intensity was
Figure 4. The tetraspan proteins CMTM5 and CD151 are novel constituents of PNSmyelin. Themyelin proteome compendiumwas systematically searched for tetraspan proteins, and those not
previously associatedwithmyelinwere experimentally analyzed.A, Immunoblot analysis of CMTM5and CD151 in sciatic nerve lysates and themyelin-enriched fraction,with equal amounts loaded.
For comparison, previously knownmyelin tetraspans (CD9, PLP/DM20, PLLP,MAL, PMP22, CD81),markers of uncompactmyelin (MAG, CNP), aswell as amitochondrialmarker (COX4) andactinwere
tested. B, C, In situ hybridization of Cmtm5 (B) and Cd151 (C) in sciatic nerves using specific cRNA probes. Scale bar, 6m. Note that Schwann cells are strongly labeled. D, E, Immunodetection of
CMTM5 (D) andCD151 (E)with 10nmgoldparticles on cross sections of sciatic nerves. Labeling for CMTM5wasmostly confined to compactmyelin (D,D) and the endoplasmic reticulumof Schwann
cells (D), while CD151 was detected in compact myelin (E, E) and the plasma membrane of Schwann cells (E). Scale bars: D, D, E, E, 200 nm; D, E, 500 nm.
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used. The 296 proteins identified by LC-MSE (see above)were iden-
tified with an average sequence coverage of 52%. Quantitative anal-
ysis of this dataset revealed that the four most abundant proteins of
PNSmyelin are P0, periaxin, MBP, and FASN, which constitute
21% [	2% relative SD (RSD)], 16	 2%, 8	 1%, and 1	 0.2%
of the total myelin protein, respectively (Fig. 5). All previously
known myelin proteins together constituted approximately half
of the total myelin protein, while all newly identified proteins
accounted for the other half. Our MS-based quantification data
take into question previous estimates based on conventional
techniques involving gel-electrophoretic separation and protein
visualizationwith SudanBlack, FastGreen, orCoomassie Blue, in
which P0, MBP, and P2 were suggested to be the most abundant
myelin constituents with 45–70, 2–26, and 2–15% of the total
myelin protein, respectively (Greenfield et al., 1973; Micko and
Schlaepfer, 1978; Smith andCurtis, 1979;Whitaker, 1981). How-
ever, gel-based estimates of the relative abundance ofmyelin pro-
teins are not very accurate. For example, the perceived high
abundance of P2 in those estimates may mainly reflect the
amount of contaminating blood, as indicated by our result that
P2 andHBA are not well separated in 1D gels (see above). Indeed,
by mass spectrometric quantification, P2 was of very low abun-
dance (0.18	 0.04%) in PNS myelin.
Myelin proteome alteration in a pathological condition
Mice harboring an inactivated prion protein gene (Prnp0/0) pro-
vide a model for a chronic polyneuropathy involving demyelina-
tion (Bremer et al., 2010). In this model, neuronally expressed
prion protein (PrPC) acts as an axonal signal to prevent demyeli-
nation. To identify candidate proteins downstream of PrPC that
could be implicated in the failure of Schwann cells to support
peripheral myelin, we systematically screened Prnp0/0 mice for
(secondary) alterations in the myelin proteome using 2D-DIGE,
comprising the labeling of myelin proteins purified frommutant
and wild-type mice with two different amine-reactive cyanine
dyes (Fig. 6A). While the overall protein profiles of wild-type
and Prnp0/0 myelin were very similar, we detected one single
spot at40 kDa that was indicative of increased abundance in
mutant myelin (calculated regulation factor 1.4; p 
 0.0053).
The constituting protein was mass-spectrometrically identi-
fied as SEPT9, and its increased abundance was confirmed by
immunoblotting (Fig. 6B). Septins are filament-forming pro-
teins with GTPase activity (for review, see Barral and Ki-
noshita, 2008) and may contribute to the myelin cytoskeleton
(Buser et al., 2009). SEPT9 is the causative gene in hereditary
neuralgic amyotrophy (HNA), for which patients harboring
point mutations (Kuhlenba¨umer et al., 2005; Hannibal et al.,
2009) or gene duplications (Collie et al., 2010) were described.
While SEPT9 was detected by immunoblotting in myelin de-
rived from both genotypes it was not mass-spectrometrically
identified in wild-type myelin, indicating that its increased
abundance in Prnp0/0myelin is a prerequisite for identification
with our stringent confidence level.
To independently confirm SEPT9 as a peripheral myelin pro-
tein, we analyzed normal sciatic nerve lysates and the myelin-
enriched fraction by immunoblotting (Fig. 6C). One band was
detected, corresponding to the smallest variant (334 aa,
ENSEMBL splice isoform Sept9–004/005; calculated molecular
weight 39 kDa). The amount of SEPT9 in myelin fractions was
lower than in nerve lysates, indicating that SEPT9 is not exclusive
to structures enriched with myelin purification such as compact
myelin. On the basis of in situ hybridization of sciatic nerves,
Sept9-mRNA is strongly expressed in Schwann cells (Fig. 6D). By
qRT-PCR, its abundance was not different between wild-type
and Prnp0/0 nerves, suggesting that the increased protein abun-
dance is a post-transcriptional effect. To address the exact local-
Protein          % (+/-RSD)
P0               20.97  (2.21)
Periaxin      16.01  (1.51)
MBP              8.25  (0.77)
Fasn             1.04  (0.17)
4.1G              0.72  (0.06)
CNP              0.54  (0.18)
CD9              0.43  (0.11) 
Annexin A2     0.41  (0.09)
CD81            0.33  (0.05)
MAG             0.28  0.05)
DRP2           0.18  (0.03)
PMP2           0.18  (0.10)
Moesin         0.15  (0.03)
PLP              0.15  (0.02)
Ezrin             0.14  (0.04)
Protein        % (+/-RSD)
Plasmolipin   0.13  (0.02)
Gelsolin      0.13  (0.01)
CA2              0.10  (0.01)
NDRG1       0.09  (0.01)
Septin 7      0.09  (0.03)
NECL4        0.08  (0.01)
Septin 2      0.08  (0.01)
Caveolin 1  0.06  (0.01)
CRYAB       0.05  (0.01)
RhoA          0.04  (0.01)
Rac1           0.04  (0.01)
Radixin       0.04  (0.01)
cdc42          0.02  (0.00)
Novel        49.18
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Novel
Figure 5. Quantification of PNS myelin proteins. Relative protein abundance was determined by LC-MS E and is given as a percentage (	RSD). Note that previously known myelin proteins
constitute approximately half of the totalmyelinprotein,while theother half are constitutedbyproteinsnot yet associatedwithmyelin. Proteinsderived fromcontaminations, suchasmitochondria,
blood, hair, and nuclei, which collectively constitute5% of the total protein amount in the fraction, were not considered for this quantification. According to MS-based quantification, the most
abundant myelin proteins are P0 (21%), Periaxin (16%), MBP (8%), and fatty acid synthase (1%). Note that MS-based quantification circumvents limitations of 1D gels such as limited resolving
power and low dynamic range of protein staining, factors that have affected previous abundance estimates based on band intensity after 1D-PAGE.
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ization of SEPT9 in vivo, we applied cryo-immuno electron
microscopy. In wild-type Schwann cells, SEPT9 labeling was re-
stricted to the abaxonal, noncompactedmyelin subcompartment
(Fig. 6F), termed the bands of Cajal (Court et al., 2004), where it
was associated with membranous structures (Fig. 6F), most likely
intracellular transport vesicles. Wild-type Schmidt–Lanterman in-
cisures were devoid of SEPT9 labeling (Fig. 6G). Interestingly,
SEPT9 was readily detectable in Schmidt–Lanterman incisures of
Prnp0/0 nerves (Fig. 6H). This suggests that the adoption of a novel
site of localization by SEPT9 underlies its increased abundance in
myelin purified from Prnp0/0 nerves and may contribute to the ob-
served chronic demyelinating polyneuropathy.
Abundance profiles of mRNAs encoding PNSmyelin proteins
To systematically analyze the postnatal abundance profiles of the
transcripts encoding the proteins in the compendium, we have per-
Figure 6. Differential peripheral myelin proteome analysis in the Prnp0/0model of chronic demyelinating polyneuropathy. A, 2D-DIGE of wild-type (WT, false-colored in blue) and Prnp0/0 (false
colored in orange)myelin. 2D-IEF/SDS-PAGEwas performedwith IEF in a nonlinear pHgradient (3–11) as the first and SDS-PAGE as the seconddimension.Most protein signals appear as black spots,
indicating that the overall protein profile is largely similar between the genotypes. One spot at40 kDa was of increased abundance in Prnp0/0myelin and identified as SEPT9. The corresponding
region of a representative gel (red frame) is shown to the right with separated detection channels. Note that the abundance of SEPT9 in wild-typemyelin was below the threshold of MS detection.
Note also the high comparability with the reference map in Figure 2A. B, Comparison of SEPT9 abundance in myelin of WT and Prnp0/0myelin by immunoblotting. Note that the abundance of the
related SEPT7 was unchanged. Quantification of SEPT9 abundance was relative to that of GAPDH. C, Immunoblot analysis of SEPT9 in brain lysates and myelin-enriched fractions. Note that the
abundance of SEPT9was reducedwithmyelin purification, different from known constituents of the compact subcompartment ofmyelin.D, In situ hybridization of Sept9 in sciatic nerves. Note that
Schwann cells are strongly labeled. Scale bar, 6m. E, Quantitative RT-PCR analysis of Sept9 in adult wild-type and Prnp0/0 sciatic nerves. Sept9-mRNA abundance was unaltered. F, Immunode-
tection of SEPT9 visualizedwith 10 nmgold particles in wild-type sciatic nerve cross sections. SEPT9 labelingwas confined to the abaxonal noncompact subcompartment ofmyelin (bands of Cajal).
The magnification shows that SEPT9 was associated with membranous structures, most likely intracellular transport vesicles (F, arrowheads). G, No labeling was found in wild-type Schmidt–
Lanterman incisures. H, SEPT9 was readily detected in Schmidt–Lanterman incisures of Prnp0/0myelin (arrowheads). Scale bars: F, 500 nm; and G, H, 200 nm.
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formedmicroarrayanalysisof sciaticnerves atpostnataldays1, 5, 15,
and 65. Unique gene identifiers were determined, and cluster analy-
sis was performed for those 528 of 545 genes that were represented
on our arrays (Fig. 7). Sept9 was also included, though detection of
SEPT9proteinbyMS inwild-typemyelinwasbelow the significance
threshold. For comparison, eight known myelin proteins not iden-
tified by MS were included [E-cadherin (gene symbol Cdh1),
-catenin (Ctnnb1), myotubularin-related protein-2 (Mtmr2),
MP11 (Mp11/A330049M08Rik), junctional adhesion molecule
(JAM4/Igsf5), connexin-32 (Cx32/Gjb1), Pmp22, andMal]. Among
the resulting 537 mRNAs, 400 showed developmental abundance
changes, including themajority of knownmyelin genes (Fig. 6). The
majority of establishedmyelinproteins displayed apostnatalmRNA
abundance peak, corresponding either to an early phase ofmyelina-
tion [P5-UP:Mag, Ctnnb1, integrin-6 (Itga6), septin 11 (Sept11)]
or a later phase [P15-UP: Mpz, Mbp, Cnp, 4.1G (Epb4.1l2), Sirt2,
Pmp2, periaxin (Prx), NECL4 (Cadm4), Mp11, and UDP-
galactosyltransferase 8 (Ugt8) (Bosio et al., 1996)]. It has been noted
previously that the abundance of a large number of mRNAs ex-
pressed in Schwann cells increases only late after myelination (e.g.,
genes involved in storage lipidmetabolism) (Verheijen et al., 2003).
The corresponding cluster (Late-UP) includes fatty acid synthase
(Fasn) (Salles et al., 2002), Cdh1, Ndrg1 (Berger et al., 2004),
dystrophin-relatedprotein2 (Drp2), caveolin-1 (Cav1) (Mikol et al.,
2002), and the actin filament-severing gelsolin (Gsn) (Gonc¸alves et
al., 2010). There is also a large cluster ofmRNAs of which the abun-
dance significantly decreases after the early stages (“descending”),
though the protein product has been identified by MS in mature
myelin. This cluster includes annexin A2 (Anxa2) (Hayashi et al.,
2007), integrin 1 (Itgb1), septin 2 (Sept2), septin 7 (Sept7), Sept9,
and ezrin (Ezr). The mRNA abundance profiles of only two genes
(Rab5c, Ap2b1) did not fit into these clusters, indicating that the set
mathematical parameters reflect the expression relationships well.
Exploiting microarray data, mRNA abundance profiles in
sciatic nerves can be evaluated systematically to determine coregu-
lated expression, but also for individual genes of interest. Inter-
estingly, the abundance profiles of the mRNAs encoding the
newly identified CMTM5 and CD151 are similar to those of
knownmyelin tetraspans (Fig. 7). Cmtm5-mRNA, like Cd9, Pllp,
Mal, and Plp1, is most abundant at P15 with a subsequent de-
cline (cluster “P15-UP”), while the abundance of Cd151
mRNA, like Cd81 and Claudin 19 (Cldn19) (Miyamoto et al.,
2005), increases to a late peak after completion of the most active
myelination (Late-UP). Interestingly, such reverse mRNA abun-
dance changes affect a number of protein families, of which sev-
eral members have been detected in myelin. For example, the
myelin marker enzyme carbonic anhydrase 2 (Car2) mRNA
abundance profile correlated with the peak of active myelination
(P15-UP), while its later decrease in matured Schwann cells goes
along with the increased abundance of carbonic anhydrase 3 (Car3,
Late-UP). Similarly, there is a shift from the Rho-GTPase Cdc42
(descending) required for Schwann cell proliferation (Benninger et
al., 2007) to the relatedRho-GTPaseRac1 required for Schwann cell
process extension and stabilization (Late-UP), and from RhoC (de-
scending) to RhoB (P15-UP). We suggest that such reverse abun-
dance changes within protein families may reflect different
functional requirements duringmyelin biogenesis versus inmature
myelin (e.g., regarding different enzymatic optima of proteins with
principally similar functions).
Importantly, robust abundance though developmentally un-
changed was observed for 46 mRNAs, including that for the glycol-
ysis enzymeGAPDH(Gapdh), but also the establishedmyelin genes
moesin (Msn), RhoA (Brancolini et al., 1999), and Pmp22 (Fig. 7).
Together, many mRNAs encoding myelin proteins exhibited the
expected abundance profile with an early postnatal peak (at
P5-P15). In contrast, the abundance of other myelin mRNAs
decreased, increased, or did not change with maturation, in-
dicating that myelin proteins are not necessarily signified by
particular mRNA abundance profiles.
Ninety-onemRNAs were either not detected at all (59) or at
very low abundance (32) (Fig. 7). The proteomic identifica-
tion of the corresponding proteins thus may partly stem from
contaminants, and indeed the group comprises all of the con-
taminating hair keratins and most of the nuclear and blood
contaminants. However, some among them are false negatives.
For example, sarcoglycan- (Sgcd) and collapsin-response medi-
ator protein 1 (Crmp1; also termed dihydropyrimidinase-related
protein 1) are established myelin proteins (D’Antonio et al.,
2006; Cai et al., 2007), though their mRNAs were not detected
in our microarray analysis. This suggests that at least some
array probes were unsuitable to detect their target mRNA,
justifying the categorization as “not detected” rather than “not
expressed.”
Functional categorization
To examine whether certain functions are over-represented in
themyelin proteome,wehave systematically analyzed the associated
gene ontology (GO) terms using the Database for Annotation, Vi-
sualizationandIntegratedDiscovery(DAVID)(david.abcc.ncifcrf.
gov). As expected, many proteins were annotated as being
involved in adhesion, but proteins involved in signaling, vesicle
transport, protein translation, and the glucose metabolism also
were over-represented (Fig. 8). For further subcategorization, we
have analyzed the GO terms for the mRNA abundance clusters
descending, Late-UP, and the combined P5/P15-UP. In accor-
dance with the stages of Schwann cell development, proteins in-
volved in protein translation were over-represented in the cluster
with the highest mRNA-abundance at P1 (descending), while
chaperones were over-represented in both the descending and
combined P5/P15-UP cluster. Interestingly, proteins involved in
the metabolism of lipids were over-represented during and after
most active myelination (P5/P15-UP, Late-UP), and proteins in-
volved in glucose metabolism were over-represented in the
Late-UP cluster. Notwithstanding that functional classification
according to previously annotated functions leads to a certain
degree of ambiguity, we suggest that the developmental shift in
mRNA abundance patterns reflects that the tasks of myelin shift
from early functions mainly regarding protein synthesis and
transport, and cellular adhesion, toward later functions re-
quiring a more active lipid and glucose metabolism.
Integrated proteomics and genetics data suggest novel
positional neuropathy candidate genes
Hereditary neuropathies can be caused by mutations affecting a
variety of genes, including many that encode myelin proteins
(Barisic et al., 2008; Pareyson andMarchesi, 2009; Reilly and Shy,
2009). Indeed, our compendium comprises the causative genes
MPZ, PRX,NDRG1, ras-related protein RAB7A, heat shock pro-
tein B1 (HSPB1), glycyl-tRNA-synthetase (GARS), and neuro-
filament light chain (NEFL) (Table 2). However, up to 50
causative genes remain unknown (Braathen et al., 2011). There-
fore, we have explored whether novel candidate genes can be
derived from our data. We have not restricted the analysis to
demyelinating neurological subtypes (CMT1) but have included
axonal subtypes (CMT2) becausemutations affecting some genes
such as MPZ or NEFL can cause either axonal or demyelinating
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Figure 7. mRNA abundance profiles of myelin-associated genes in developing sciatic nerves. A, K-means clustering was performed for those 529 of 546 proteins in our compendium for which
corresponding oligonucleotides were present on the arrays. Eight genes marked with an asterisk were additionally included for comparison, though the proteins were not identified by MS. The
normalizedmRNA abundance profiles are plottedwith regard to the age (mouse postnatal days 1, 5, 15, and 65). Geneswith significantmRNA abundance changeswere categorized in five clusters,
and genes with developmentally unchanged expression were grouped according to mRNA abundance. Known myelin genes are in bold, the novel myelin genes Cmtm5 and Cd151 are in red, and
genes encoding mitochondrial, blood, hair, or nuclear proteins are in gray. In clusters P5-UP and P15-UP, the mRNA abundance is highest around the peak of myelination, while mRNA abundance
in cluster Late-UP is highest after developmental myelination. mRNAs in cluster descending are significantly suppressed during development, though the corresponding proteins were identified in
mature myelin. Note that a significant number of mRNAs is developmentally unchanged. B, The numbers of mRNAs per cluster are given. Note that only twomRNAs show developmental changes
not fitting in any cluster.
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pathology (Vance, 2000). We have also not excluded genes ac-
cording to prior knowledge of spatiotemporal expression, as sev-
eral disease-causing genes are expressed in both neurons and
Schwann cells, such asGARS (Cuesta et al., 2002; Verheijen et al.,
2003) andNEFL (Roberson et al., 1992; Previtali et al., 2003). For
543 (of 545) proteins in our compendium, we were able to deter-
mine the chromosomal localization of the corresponding human
homologous gene using SNPper (snpper.chip.org), the Univer-
sity of California, Santa Cruz, Genome Bioinformatics Suite
(genome.ucsc.edu), Entrez Gene (ncbi.nlm.nih.gov/gene), and
blast search validation (when required). The comparison with 16
chromosomal segments previously associated with neuropathy
suggested 59 candidate genes for 14 distinct loci (Table 2); for
example, CMT3C maps to chromosomal segment 8q23–q24,
comprising 204 genes. Three of them [oxidation resistance 1
(OXR1), N-myc downstream regulated gene-1 (NDRG1), and
plectin (PLEC1)] encode proteins that were identified in our
screen, making them attractive candidate neuropathy genes.
Discussion
We have established the first proteomic analysis of PNS myelin.
Among 545 identified proteins, our compendium includes al-
most all known myelin proteins, indicating that the proteomic
approach was appropriate for systematic analysis. Focusing on
tetraspan-transmembrane proteins, we have proven that indeed
myelin constituents were newly identified. We have also inte-
grated the compendium with various systematic approaches,
namely the following: (1) mRNA abundance profiles in periph-
eral nerves; (2) transmembrane domain prediction according to
three algorithms; (3) subcellular localization prediction accord-
ing to four algorithms and comparison with the brainmitochon-
dria proteome; (4) over-represented functions; (5) association of
the corresponding human genes with neuropathy disease loci;
and (6) comparison with the CNS myelin proteome.
The identification of hundreds ofmyelin proteins necessitates
reconsidering the long-standing view that PNS myelin contains
only a few proteins, which was shaped in early studies in which
only three bands (designated P0, P1, P2) were visible after myelin
separation by 1D-SDS-PAGE followed by Fast-Green, Buffalo-
Black, or Coomassie labeling (Greenfield et al., 1973; Micko and
Schlaepfer, 1978). Later analyses revealed 15–25 bands (Gillespie
et al., 1994), the majority of which were constituted by unidenti-
fied proteins. Since the 1970s, the number of myelin proteins
increased to 40, often upon the genetic identification of neu-
ropathy disease genes or mRNA microarray analyses filtering
data for abundance changes during nerve development or in dis-
ease (Verheijen et al., 2003; Buchstaller et al., 2004; D’Antonio et
al., 2006; Ryu et al., 2008). These studies clarified many develop-
mental and pathological processes but were not suited to system-
atically analyze myelin protein composition because myelin
proteins are not necessarily signified by particular mRNA abun-
dance profiles and genes expressed in Schwann cells not neces-
sarily encode myelin proteins. Unbiased proteomic approaches
as pursued here circumvent these problems.
For the present study, myelin was purified using an essentially
unchanged protocol. The key to comprehensiveness was the ap-
plication of complementary proteomic approaches. In our
hands, gel-based and gel-free methods identified rather similar
numbers of proteins. However, gel-free analyses required less
starting material by a factor of 10–100 compared with 2D gels.
However, 2D-IEF/SDS-PAGE was important as it increased the
coverage ofmyelin proteins (93 unique identifications), provided
a two-dimensional reference map, and enabled differential my-
elin proteome analysis by 2D-DIGE. Gel-free LC-MSE was very
powerful as it yielded quantitative data on thousands of tryptic
peptides, allowing us to readjust the relative abundance ofmyelin
proteins. The MS-based quantification of P0 (21%), periaxin
(16%), and MBP (8%) supports that particular myelin proteins
are of predominating abundance. However, theMS-based values
are moderate compared with gel-based estimates, in which P0
and MBP were considered to constitute an extraordinarily high
50–70% and 15% of the total myelin protein, respectively (Gar-
bay et al., 2000). Thus, the large-scale identification of low-
abundant proteins goes along with a lower relative abundance of
any individual myelin protein. Importantly, gel-based abun-
dance estimates were hampered by insufficient 1D separation.
For example, P2 was estimated to constitute 2–15%, depending
on the species and the study (Whitaker, 1981).However, we show
that in 1D gels P2 comigrates with hemoglobin-A and by MS
quantification constitutes only 0.2% of the total myelin pro-
tein. Therefore, gel-based estimates of P2 abundance may actu-
ally represent a measure of contamination with blood.
Although we used state-of-the-art proteomic techniques, we
failed to identify certain established PNSmyelin proteins, reflect-
ing technical limitations particularly affecting small membrane-
tetraspans such as PMP22 (18.0 kDa) (Naef and Suter, 1998;
Mu¨ller, 2000) and MAL (16.6 kDa) (Schaeren-Wiemers et al.,
2004). Complete tryptic digestion of these proteins does not re-
sult in any peptide appropriate for MS sequencing because their
tryptic cleavage sites are atypically distributed and membrane-
spanning peptides are barely detected by MS. Thus, improved
enrichment protocols formembrane-spanning proteins, usage of
alternative proteases (e.g., elastase) (Rietschel et al., 2009), and
technical advancements inMSmay expand the myelin proteome
even further.
Improved coverage of low-abundant proteins goes along with
more identified contaminants. The myelin-enriched fraction
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Figure 8. Functional categorization. The proteins identified in PNSmyelin (in black) and the
mRNA clusters descending (dark gray), P5/P15-UP (gray), and Late-UP (light gray) were ana-
lyzed for over-represented functional annotations using gene ontology terms. For comparison,
myelin proteins known according to the literature were annotated. Mitochondrial, hair, blood,
and nuclear proteins were omitted. The histogram indicates the percentage of proteins within
each cluster that have been annotatedwith the particular function. n.o., Not over-represented.
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from peripheral nerves doubtless contains contaminants, includ-
ing mitochondria (with similar flotation properties) and axonal
membranes (associated via adhesion proteins). As absolute
purity may not be gained even with improved protocols, we
attempted specifying likely contaminants. First, axonal contam-
inants were predicted by comparison with mRNA microarray
data as the neuronal cell bodies are outside of the nerve segment
used for proteome analysis. Neuronal mRNAs would be not
detected in sciatic nerves (although some unsuitable oligonu-
cleotides on microarrays lead to false negatives). Second,
software-based prediction of subcellular localization and com-
parisonwithmitochondrial proteome datasets determinedmito-
chondrial contaminants with reasonable probability (10.5% of
proteins in our dataset). Interestingly, a considerable number of
mitochondrial proteins have a dual localization (Pagliarini et al.,
2008), suggesting that some may additionally be myelin constit-
uents. Thus, software-based prediction of subcellular localization
is valuable for proteins with sorting motifs but should be taken
cautiously because some are ambiguous or irrelevant in vivo, and
predictions by different algorithms can be conflicting. For exam-
ple, MBP, DRP2, 4.1G, and periaxin are efficiently incorporated
into myelin although they contain polybasic motifs consistently
interpreted by software as nuclear targeting signals. Together, we
estimate that contaminant proteins from hair, blood, and nuclei
collectively comprise5% of our compendium. Thus, we calcu-
late that 400 proteins of the 545 in our dataset (representing
95% of the total protein amount in the myelin-enriched frac-
tion) are true myelin constituents, though immuno-based vali-
dation will ultimately be required. All proteins identified by MS
in PNS myelin that were also validated with independent meth-
ods are given in Table 3.
Systematic prediction of transmembrane domains suggested
that CMTM5 and CD151 are novel myelin-tetraspans, a protein
class with proven relevance formyelin (Bronstein, 2000). Indeed,
we visualized their mRNAs in Schwann cells by in situ hybridiza-
tion, revealed their mRNA abundance profiles in sciatic nerves,
and detected both proteins in compactmyelin by immuno-based
methods. Like other myelin proteins, they are not exclusive to
myelin but expressed in a range of tissues, though enriched in
myelin. For example, expression of the tetraspanin CD151 was
noted in the lung, kidney glomeruli, and platelet cells (Caplan et
al., 2007; Goschnick and Jackson, 2007) where it regulates integ-
rin signaling (Yunta and Lazo, 2003; Baldwin et al., 2008), which
is also crucial for myelination (Berti et al., 2006). A characteriza-
tion of native tissue expression of CMTM5 is yet unavailable,
though it has been suggested as a potential tumor suppressor
(Shao et al., 2007, 2009; Guo et al., 2009). CMTM5 is related to
MAL and plasmolipin regarding the presence of a MARVEL do-
main implicated in membrane apposition (Sa´nchez-Pulido et
al., 2002), and to chemokine-like proteins. Thus, CD151 and
CMTM5 not only represent novel myelin markers, they are also
likely relevant to the biogenesis and structural organization of
PNS myelin, which will be specified in future gene-targeting
experiments.
Differential myelin proteome analysis in the Prnp0/0 neurop-
athy model (Bremer et al., 2010) revealed the strongly increased
abundance of SEPT9, related to its presence in Prnp0/0 mutant
Schmidt-Lanterman incisures additional to its normal localiza-
tion in the bands of Cajal. SEPT9 is expressed in many tissues
(Scott et al., 2005) and more abundant in Schwann cells than in
neurons (Sudo et al., 2007). Septins can assemble into filaments
and have been implicated in regulating microtubules and vesicle
trafficking (Peterson and Petty, 2010). Duplication of the whole
SEPT9 gene causes the neuropathy HNA (Collie et al., 2010), and
point mutations (Kuhlenba¨umer et al., 2005) dramatically increase
SEPT9–mRNAtranslation(McDadeet al., 2007), suggesting that the
Table 2. Comparison of neuropathy disease loci and proteins identified in PNSmyelin
Disease OMIM no. Locus Genes in locus Myelin associated genes
Neuropathy with known disease gene Proven neuropathy gene
CMT1B/2I/2J/3B, DSS 159440 1q23.3 28 MPZ
CMT2B 602298 3q21.3 42 RAB7A
CMT2D, HMN5A 600287 7p15 84 GARS
CMT1F/2E 162280 8p21 87 NEFL
CMT2F, HMN2B 602195 7q11.23 86 HSPB1 (HSP27)
CMT3D/4F, DSS 605725 19q13.13-q13.2 136 PRX
CMT4D 605262 8q24.22 108 NDRG1*
HNA 162100 17q25 94 SEPT9
Neuropathy lacking a known disease gene Candidate neuropathy genes
CMT2C, DSMA 606071 12q23-q24 304 VPS29, RAN, CKAP4, DYNLL1, ERP29, ALDH2, HSP90B1, RAB35, SLC25A3
CMT2G 608591 12q12.2-q13.3 307 ARF3, KRT, PRPH, ATP5B, CS, COL2A1, DCTN2, GPD1, FAM62A
DI-CMTA 606483 10q24.1-q25.1 129 PGAM1, INA, ARP1, GOT1, SFXN3
CMT3C NA 8q23-q24 204 OXR1, NDRG1, PLEC1
CMT4G 605285 10q23.2 18 GLUD1
CMT4C2 NA 8q21.2-q21.3 21 CA2, CA3, GDAP, PMP2, FABP4
CMTX2 302801 Xp22.2 48 NA
CMTX3 302802 Xq26 54 HPRT1
CMTX4 310490 Xq24-q26.1 77 SLC25A5, PGRMC1
HMN7A 158580 2q14 53 ACTR3, TSN
HMN3, HMN4, DSMA3 607088 11q13 268 PC, STIP1, SERPINH1, CFL1, PRDX5, RAB6A, RAB1B, EHD1, GSTP1, DHCR7, RTN3
HMN-J, DSMA2 605726 9p21.1-p12 123 TLN1, VCP, TPM2, ALDH1B1
HMN-X NA Xq13-q22 210 DRP2, PLP1
HSAN1B 608088 3p22-p24 134 PDCD6IP, RAB5A
HSAN with SPG NA 5q15.31-q14.1 82 NA
HSAN with deafness NA Xq23-q27.3 174 SLC25A5, HPRT1, PGRMC1
Proteins identified byMS in sciatic nervemyelinwere analyzedwith respect to the localization of the corresponding gene in the humangenome for comparisonwith neuropathy disease loci. *Note that CMT4Dhas been previously associated
with 8q24.3 while the causative gene (NDRG1) is located at 8q24.22. CMT, Charcot-Marie-Tooth disease; DSS, Déjerine-Sottas syndrome; HMN, hereditary motor neuropathy; HSAN, hereditary sensory and autonomic neuropathy; NA, not
applicable; OMIM, Online Mendelian Inheritance in Man.
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SEPT9 dosage is pathophysiologically relevant (van Alfen, 2011). In
comparison, themost frequent cause of CMT is a duplication of the
PMP22gene (Barisic et al., 2008).Together, the requirementofPrnp
for the normal abundance and localization of SEPT9 in peripheral
myelin implies that neuronal Prnp contributes to axon-to-Schwann
cell signaling related to the myelin cytoskeleton and long-term
myelin maintenance. The exact abundance of SEPT9 in
Schwann cells may not only be related to the (yet speculative)
pathomechanism of HNA (mainly affecting the brachial
plexus) but also to other neuropathies, possibly by interfering
with the normal formation or stability of SEPT9-containing
filaments.
This first proteomic approach to peripheral myelin provides
evidence that its molecular composition is much more complex
and that the relative abundance of P0 and MBP is less extreme
than thought. Two tetraspans were established as novel constitu-
ents of compact myelin. While we cannot ultimately validate the
presence of all identifiedproteins, the integrationwithother system-
atic datasets allows the prediction of400 truemyelin proteins.We
also provide categorization according to developmentally coregu-
lated mRNA abundance. We noted that not only expected func-
tional annotations such as adhesion and the lipid metabolism are
over-represented in the myelin proteome but also the glucose me-
tabolism. Finally, we have predicted novel candidate genes to cause
(whenmutated) hereditary neuropathies.Manyproteinswere iden-
tified in both PNS and CNS myelin, suggesting that Schwann cells
and oligodendrocytes have recruited surprisingly similar proteins
into myelin. However, differential protein distributions appear at
least as relevant, as exemplified by the shift from P0 to PLP as the
most abundant CNS myelin protein at the evolutionary transition
from fish to tetrapods (Yoshida and Colman, 1996). Together, our
compendium provides a framework to analyze myelination and
glia–axonal interactions, the functions ofmyelin in insulating axons
and preventing them from degeneration, and molecular changes in
myelin-related disease.
Notes
The compendium of MS-identified proteins, including SwissProt/Uni-
Prot accession numbers, acronyms, subcellular localization according to
three algorithms (Cello, Wolfpsort, Subloc), presence of signal peptides
Table 3. Mass-spectrometrically identifiedmyelin proteins additionally validated with immuno-basedmethods
Protein name Gene MSmethod Reference TMD Cluster CNS
Annexin A2 Anxa2 I,B,S,D,E,wS,wE,wSE Hayashi et al., 2007 Descend N
Band 4.1 protein G Epb41l2 B,S,D,E,wS,wE,wSE Ohno et al., 2006 P15-UP N
Carbonic anhydrase 2 Ca2 I,D,E Cammer et al., 1987 P15-UP N
Caveolin 1 Cav1 S,E,wSE Mikol et al., 2002 1 Late-UP N
CD151 Cd151 S,wS This article 4 Late-UP N
CD81 Cd81 D,E,wE,wSE Ishibashi et al., 2004 4 Late-UP Y
CD9 Cd9 S,D,E,wS,wE,wSE Ishibashi et al., 2004 4 P15-UP N
Cell adhesion molecule 4, NECL4 Cadm4 I,S,D,E,wS,wSE Spiegel et al., 2007 1 P15-UP Y
Cell division control protein 42 Cdc42 I,E,wSE Benninger et al., 2007 Descend Y
CKLF-like MARVEL TMD-containing 5 Cmtm5 wS,wSE This article 4 P15-UP N
Claudin 19 Cldn19 wSE Miyamoto et al., 2005 4 Late-UP N
CNP Cnp I,B,S,D,E,wS,wE,wSE Matthieu et al., 1980 P15-UP Y
Crystallin2 Cryab I,S,D,E,wS,wSE d’Antonio et al., 2006 P15-UP Y
Dihydropyrimidinase related 1 Crmp1 E d’Antonio et al., 2006 ND Y
Dystrophin-related protein 2 Drp2 E Sherman et al., 2001 Late-UP N
Ezrin Ezr I,E Scherer et al., 2001 Descend Y
Fatty acid synthase Fasn S,D,E,wS,wE,wSE Salles et al., 2002 Late-UP Y
Gelsolin Gsn I,S,D,E,wSE Gonçalves et al., 2010 Late-UP Y
Integrin6 Itga6 I,D,wSE Nodari et al., 2008 1 P5-UP N
Integrin1 Itgb1 wSE Feltri et al., 2002 1 Descend N
Moesin Msn I,B,S,D,E,wSE Scherer et al., 2001 Unchanged Y
Myelin associated glycoprotein Mag S,D,E,wS,wSE Figlewicz et al., 1981 1 P5-UP Y
Myelin basic protein Mbp I,B,S,D,E,wS,wE,wSE Boggs, 2006 P15-UP Y
Myelin protein 2, PMP2 Pmp2 I,B,S,D,E,wS,wE,wSE Trapp et al., 1984 P15-UP N
Myelin protein zero, P0 Mpz I,B,S,D,E,wS,wE,wSE Giese et al., 1992 1 P15-UP Y
Myelin proteolipid protein Plp1 B,S,D,E,wS,wE,wSE Garbern et al., 1997 4 P15-UP Y
NDRG1, N-myc downstream regulated Ndrg1 I,D,E,wS,wE,wSE Berger et al., 2004 Late-UP Y
Periaxin Prx I,B,S,D,E,wS,wE,wSE Gillespie et al., 1994 P15-UP N
Plasmolipin Pllp S,E,wS,wSE Bosse et al., 2003 4 P15-UP Y
Rac1 Rac1 I,S,D,E,wSE Benninger et al., 2007 Late-UP Y
Radixin Rdx I,E Scherer et al., 2001 U-shape Y
RhoA Rhoa I,D,E,wSE Brancolini et al., 1999 Unchanged Y
Sarcoglycan  Sgcd wSE Cai et al., 2007 1 ND N
Septin 11 Sept11 I Buser et al., 2009 P5-UP Y
Septin 2 Sept2 I,D,E Buser et al., 2009 Descend Y
Septin 7 Sept7 D,E,wSE Buser et al., 2009 Descend Y
Septin 9 Sept9 2D-DIGE This article Descend N
Sirtuin 2, NAD-dependent deacetylase Sirt2 I,wSE Werner et al., 2007 P15-UP Y
UDP galactosyltransferase 8 Ugt8 wSE Bosio et al., 1996 1 P15-UP N
The proteins identified in peripheral myelin by MS have been compiled according to availability of validation with immuno-based methods. The methods of MS identification are as follows: S, GeLC; wS, wash-GelC; wSE, wash-GeLC-MSE;
I, 2D-IEF/SDS-PAGE; B, 2D-16BAC/SDS-PAGE; D, LC-DDA; E, LC-MSE; wE, wash-LC-MSE. One selected reference is given in which presence in peripheral myelin was validated. Additionally given are the number of transmembrane domains
(TMDs), the mRNA abundance profile cluster, and whether a protein was also identified by mass spectrometry in CNSmyelin according to the compilation by Jahn et al. (2009) (CNS: Y, also identified in CNSmyelin; N, not identified in CNS
myelin). The complete compendium of MS-identified proteins will be hosted on the author’s web page (see Notes). Tetraspan proteins are in bold. ND, mRNA not detected.
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or mitochondrial targeting signals, spot numbers for proteins identified
from 2D gels according to Figure 2, relative abundance of proteins iden-
tified by LC-MSE (in parts permillion), andmRNA abundance profile, is
available at http://www1.em.mpg.de/myelinproteome. This material has
not been peer reviewed.
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